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The emergence of Staphylococcus aureus exhibiting intermediate
levels of resistance to glycopeptides (GISA) has been expected
for a long time. After more than 30 years of vancomycin use,
true resistance to glycopeptides emerged in clinical isolates of
enterococci and Streptococcus bovis, as well as low-level glyco-
peptide resistance in coagulase-negative staphylococci [1^4].
Moreover, since it has been possible to transfer vancomycin
resistance genes from enterococci to Staphylococcus aureus in the
laboratory, there has been concern about the possibility of the
occurrence of this phenomenon among clinical isolates [5].
Although to date this has not occurred, in 1997 a strain of
methicillin-resistant Staphylococcus aureus (MRSA) with inter-
mediate resistance to vancomycin (VISA) that was associated
with therapeutic failure was reported in Japan [6,7]. This ¢rst
description was followed by several reports from the USA,
Europe and Asia [8^17]. Because few therapies are available to
treat MRSA, the con¢rmed reports of strains demonstrating
reduced susceptibility to vancomycin, which has been the
drug of last resort to treatMRSA,were of concern.
But what is aVISA isolate? The acronymsVISA (vancomy-
cin-intermediate Staphylococcus aureus) and GISA (glycopep-
tide-intermediate Staphylococcus aureus) have been used to
describe Staphylococcus aureus isolates with reduced susceptibil-
ity to vancomycin.The term GISA is a technically more accu-
rate description of VISA strains, since many GISA isolates
have shown intermediate-level MICs to the glycopeptide
drugs vancomycin and teicoplanin. The National Committee
for Clinical Laboratory Standards de¢nes GISA isolates as
those having vancomycin MICs of 8^16mg/L (intermediate)
and a teicoplaninMIC of16mg/L (intermediate) [18]. It seems
that we can now ¢nd Staphylococcus aureus strains showing
intermediate resistance to glycopeptides in many parts of the
world; however, this is not a new phenomenon. As early as
1956, it was shown that, by means of serial passage on media
containing vancomycin, it was possible to produceStaphylococ-
cus aureuswith reduced susceptibility to vancomycin [19,20]. A
study in Germany [8] demonstrated that strains showing
intermediate resistance to vancomycin had been present in that
country at least since 1993. Another study in Spain [21]
demonstrated the presence of such isolates since 1990, and in a
recent retrospective analysis of susceptibilities of Staphylococcus
aureus performed in our laboratory, we have found that vanco-
mycin-intermediate strains have been present at least since
1992. It is surprising that there have not been more reports of
these microorganisms in other countries before, but this is
probably because they have not previously been sought out
and have been overlooked. Moreover, detection of GISA iso-
lates can be di¤cult. Like MRSA, GISA may show hetero-
resistance, and slower-growing cells within a culture that
express resistance to vancomycin can be di¤cult to detect with
commonly used susceptibility testing methods [14]. For this
reason, Staphylococcus aureus strains with vancomycin MICs of
4mg/L (susceptible but raised MIC) should be sought, so that
they can be further evaluated as potential sources of treatment
failures. In this regard, we must choose an appropriate routine
susceptibility testing method to detect GISA. Disk di¡usion
testing and MicroScan rapid panels cannot detect GISA iso-
lates, and the current version of Vitek software may not report
vancomycin MICs above 4mg/L. In general, MicroScan con-
ventional panels and E test can detect staphylococci with
decreased susceptibility to vancomycin when the tests are
incubated for a full 24 h before reading. For large-scale screen-
ing for GISA, the Mueller^Hinton agar screen plate contain-
ing 5 mg of vancomycin per mL provides a sensitive and cost-
e¡ective method [22,23]. Another aspect that still remains to
be elucidated is the exact mechanism for this reduced suscept-
ibility, although it appears to involve augmentation of cell
wall synthesis resulting in binding of glycopeptides, hyperex-
pression of penicillin-binding proteins (mainly PBP2), altera-
tions in PBP4 and production of capsule type 5 [24^27].
On the other hand, the true clinical signi¢cance of these
isolates is not clear [28]. Most reports of patients infected with
GISA have presented poor outcomes; however, many of the
patients died of other causes, and others had undrained foci of
infection or foreign bodies, which decrease the e¡ectiveness of
vancomycin [13^15,17,21,29]. This situation is again not new,
since the persistence of positive blood cultures in patients with
endocarditis during vancomycin therapy has been described
[30].These patients would probably have responded to vanco-
mycin if given in adequate dosages for a long enough period of
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time (serum levels of vancomycin above the MIC for all of
the dosing period), as recently reported [26,31]. Other studies
indicate that the coincidence of GISA strains with orthopedic
devices in the same group of patients makes it di¤cult to clar-
ify their relative contributions to the poor outcome [21]. In
any case, in the setting of using vancomycin for di¤cult-to-
treat infections for prolonged periods, GISA strains may con-
tribute to poor outcomes, and their detection may be of clini-
cal relevance. At present, it remains to be elucidated whether
full-dose vancomycin therapy will be of bene¢t for such
patients. Meanwhile, we have to deal with the detection of
these isolates in the laboratory by improving our laboratory
methods to detect such strains and monitor their emergence,
especially in patients unresponsive tovancomycin therapy.
The ¢nding of GISA isolates in clinical samples may be a
more common and older problem than has generally been
recognized but cannot be ignored.
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